Microcap Ledger Adial Pharmaceuticals, Inc. $ADIL
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Charlottesville, VA
- Fiscal year end
- December 31
- Shares outstanding
- 2,625,890 [10-Q 2026-08-14]
What the company doesAI summary of filing
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing AD04, an investigational drug candidate for treating alcohol use disorder in patients with specific genetic variants. AD04 uses ondansetron, a generic active ingredient, paired with a companion diagnostic genetic test to identify patients most likely to benefit. The company has completed a Phase 3 clinical trial called ONWARD and is currently pre-revenue, having incurred net losses since inception and generated no product revenues. Adial is planning additional Phase 3 trials to meet FDA requirements for approval primarily in the US and secondarily in Europe. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$54.01M | −$7.97M | $28.71M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$7978.00B | −$6.49M | $5.88M | [DEF 14A 2026-08-24] |
| FY ended Dec 2024 | — | −$13197.00B | −$6.92M | $3.75M | [DEF 14A 2026-08-24] |
- Quarterly cash burn
- −$3.99M
- Cash runway Estimate
- ~21.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-12 | 6,405,781 | [10-Q 2024-11-13] |
| 2025-02-28 | 6,574,588 | [10-K 2025-03-04] |
| 2025-05-13 | 7,900,695 | [10-Q 2025-05-14] |
| 2025-08-08 | 21,828,215 | [10-Q 2025-08-13] |
| 2025-11-07 | 23,987,587 | [10-Q 2025-11-13] |
| 2026-03-04 | 1,427,970 | [10-K 2026-03-05] |
| 2026-05-06 | 2,143,621 | [10-Q 2026-05-08] |
| 2026-08-12 | 2,625,890 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-08-28; no effectiveness notice found in EDGAR [S-3 2026-08-28]
Listing status
Current status: 4 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-21. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-21] |
| 2025-09-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-09-03] |
| 2025-05-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-30] |
| 2025-03-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-07] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-16 | Coastlands Capital Lp | buy | 1,233 | $2.75 | [4 2026-07-16] |
| 2026-07-14 | Coastlands Capital Lp | buy | 2,000 | $2.65 | [4 2026-07-16] |
| 2026-07-10 | Coastlands Capital Lp | buy | 1,700 | $2.70 | [4 2026-07-13] |
| 2026-07-09 | Coastlands Capital Lp | buy | 10,053 | $2.79 | [4 2026-07-13] |
| 2026-06-29 | Coastlands Capital Lp | buy | 25,000 | $2.60 | [4 2026-07-01] |
| 2026-06-12 | Davidson Matt | grant | 232,417 | — | [4 2026-06-16] |
| 2026-06-11 | Davidson Matt | grant | 61,647 | — | [4 2026-06-16] |
| 2026-06-11 | Davidson Matt | grant | 3,427 | — | [4 2026-06-16] |
| 2026-06-11 | Davidson Matt | grant | 1,822.13 | — | [4 2026-06-16] |
| 2026-06-11 | Davidson Matt | grant | 101.298 | — | [4 2026-06-16] |
| 2026-04-07 | Goodman Tony | grant | 26,510 | — | [4 2026-04-09] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-02 | 8-K | Other events |
| 2026-09-18 | 8-K | Director or officer change; Shareholder vote results |
| 2026-09-16 | 8-K | Material agreement entered; Other events |
| 2026-08-28 | S-3 | Registration statement |
| 2026-08-25 | 8-K | Unregistered sale of equity |
| 2026-08-24 | DEF 14A | Proxy statement |
| 2026-08-21 | 8-K | Listing notice or transfer |
| 2026-08-17 | 8-K | Results of operations |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Director or officer change; Other events |
| 2026-08-11 | PRE 14A | Proxy statement |
| 2026-07-01 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $ADIL
Email me when Adial Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.